I graduated summa cum laude with a Bachelor of Science from Rocky Mountain College. I'm a former Edward Jones Financial Advisor who worked at Edward Jones Headquarters, in St. Louis, Missouri, handling multiple offices in transition. The cumulative assets for the team I was on totaled over 400 million in assets under care. I then proceeded to take over a branch in Coeur d'Alene, Idaho. I now trade, speculate, and invest on my own account for a living. (Transcendentalist/Existentialist)
I am a Chartered Accountant (CA) from India and have passed the CPA exam in the US. I have worked as a finance analyst in multinational companies, have extensive experience in data analysis, business valuations and company valuations.
I have been investing over the past several years and building my nest egg with my Roth IRA and Roth 403b, Time is my best friend - and I have more than most - so I look at long-term investing and often times invest with the mindset of where the stock will be in 3+ years from when I buy. My investments vary by sector with the exception of REITs, which you will find I write about half the time on this site. I typically focus on dividend growth investing, but also like to look for value opportunities when they present themselves. I dabble in options rarely, and only when I see a substantial opportunity. I do not consider trading options a core principle in my investing practices.
If you are a dividend growth investor, can stand my poor grammar (I'll admit it's not the best), and want some long-term ideas, feel free to follow me on this site.
All the best,
Taylor Dart is a top contributor on Seeking Alpha in both the Long Ideas and Precious Metals section of the website. He has over 10 years of experience in active investing with a compound annual growth rate of 19 percent per year. His main focus is on undervalued growth stocks outperforming the market and their peers. In addition he use extensive technical analysis to capture maximum upside price action, as his belief is that timing is everything. Taylor scans upwards of 1200 stocks nightly on the U.S. and Canadian markets to identify the best fundamental opportunities with the most timely technical setups. He is a huge proponent of trend following and the "Turtles" who enjoyed compound annual growth rates of over 80 percent per year.
"If there is a sudden range expansion in a market that has been trading narrowly, human nature is to try and fade that price move. When you get a range expansion, the market is sending you a very loud, clear signal that the market is getting ready to move in the direction of that expansion.” - Paul Tudor Jones
"While a fundamental analyst may be able to properly evaluate the economics underlying a stock, I do not believe they can predict how the masses will process this same information. Ultimately, it is the dollar-weighted collective opinion of all market participants that determines whether a stock goes up or down. This consensus is revealed by analyzing price."
Mark Abraham , Quantitative Capital Management, L.P.
"Profit targets imply a trader can predict the future. Profit targets are profit-limiting. Trend followers stay in the moment of now, avoid prognostication, and let markets run as far as they go. "
Thomas Vician, Jr.
"We can’t always take advantage of a particular period. But in an uncertain world, perhaps the investment philosophy that makes the most sense, if you study the implications carefully, is trend following. Trend following consists of buying high and selling low. For 19 years we have consistently bought high and sold low. If trends were not the underlying nature of markets, our type of trading would have very quickly put us out of business. It wouldn’t take 19 years or even 19 months of buying high and selling low ALL of the time to bankrupt you. But trends are an integral, underlying reality in life. How can someone buy high and sell low and be successful for two decades unless the underlying nature of markets is to trend? On the other hand, I’ve seen year-after-year, brilliant men buying low and selling high for a while successfully and then going broke because they thought they understood why a certain investment instrument had to perform in accordance with their personal logic. "
John W. Henry
Michael Kramer is the founder and PM of MCM.
Michael Kramer is a thematic growth investor. He likes to think about themes in society and find long term equity investments that fit those themes.
Michael is the founding member of Mott Capital Management, LLC in 2014. Prior to MCM Michael spent the previous 10 years working as a domestic and international equity trader. During this time he was responsible for handling trades in some of the most illiquid equities. Additionally, Michael has experience trading in some of the most exotic foreign markets.
Mott Capital Management is a Thematic Growth investor using themes and trends in life to find exciting growth stories. Once we find a theme we want to capitalize on we begin searching for products that interact with the end user. From there we begin the company search process. We are long-term because that is our edge. We understand and recognize when events are critical and when they are not. We also believe it is a way to neutralize market volatility.
25 years in energy M&A/Corporate Finance business career. Senior officer for public E&P companies, including MLP, charged with overseeing (at different times) accounting, tax, legal, investment banking/analyst relations, investor relations, as well as business unit with land, engineering, geological and support functions. Used legal background to interface with and direct outside investment bankers, law firms and accounting firms in M&A transactions and offerings. Personal investments and trading 15 years.
I am an independent equities trader focused on uncovering unknown gems in the market. I graduated from UCLA in 2012 with a degree in Biology and am mostly focused on trading the Biotechnology sector. I look for stocks that have upcoming catalyst events which are under the radar and undervalued by the market. I am the Director and Co-founder of BiotechBreakouts.com, where I look to capture the biggest percentage gains, while minimizing risk.
I am a lecturer at the University of Economics in Bratislava, department of Banking and International Finance. I have a Ph.D. academic degree, my dissertation was focused on commodity markets. Commodities and stock markets are also the main focus of my research and publication activitities.
I have approximately 10 years of investing experiences. My investments mostly focus on small- to mid-cap companies of resource sector, utilities and biotechnologies. I prefer long positions. I never short.
The Clinically Sound Investor is a pharmacist with a PharmD and a BA in psychology. He has worked across the spectrum from very small independent and hospital pharmacies to the some of the largest retail corporations and medical centers in the nation, as well as experience in specialty and mail order settings. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results. His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
Jim Roumell is Founder and President of Roumell Asset Management, LLC. Mr. Roumell founded the firm in 1998 after more than a decade as a financial advisor. Mr. Roumell is highlighted in, “The Art of Value Investing: How the World’s Best Investors Beat the Market” by John Heins and Whitney Tilson. Martin J. Whitman, Founder of Third Avenue Value Funds, says, "Jim's investment philosophies and his actual investments snugly fit into my criteria for securities investment." Mr. Roumell was selected to participate in, and won, two consecutive Wall Street Journal stock picking contests (in 2001 and 2002) before the contest was discontinued. He is a graduate of Wayne State University, Detroit, Michigan.
After completing both a PhD in physiology and an MBA, I am interested in leveraging both areas of expertise to provide in depth analysis of the biotech sector. I began analyzing and covering biotech stocks in 2006. My interest in this sector is a result of my past experience in this industry which ranges from R&D to strategic management at several large and small biotech firms. With a broad scientific background and formal training in finance, I seek to leverage my knowledge and industry experience to provide a deep understanding of the markets and science that drive value in microcap healthcare stocks.
The material presented in these reports is provided for information purposes only and is not to be used or considered as a recommendation to buy, hold or sell any securities or other financial instruments. Information contained herein has been compiled and prepared from various public and industry sources that I believe to be reliable; however, no representation or warranty is expressed or implied as to the accuracy or completeness of the information. Such information is provided with the expectation that it will be read as part of a broader analysis and should not be relied upon on a stand-alone basis. Past performance should not be taken as an indication or guarantee of future performance, and I make no representation or warranty regarding future performance. The opinions expressed in this report reflect my judgment as of the date of this report and are subject to change without notice. These reports are not an offer to sell or a solicitation of an offer to buy any securities. The offer and sale of securities are regulated generally in various jurisdictions, particularly the manner in which securities may be offered and sold to residents of a particular country or jurisdiction. Securities discussed in these reports may not be eligible for sale in some jurisdictions. To the full extent provided by law neither myself nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein. I am not on the Board of Directors of a covered company. I do not invest in the securities of the company that is the subject of these reports unless otherwise indicated. I have not been compensated by the company that is the subject of these reports.
MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies. Licensed Investment Advisor.
Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform.
Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Joe has worked in the financial services industry since 1992 in various capacities, including Operations Manager, Compliance Manager, Registered Representative and Portfolio Manager. From 1997 to 2006, when he founded Alhambra Investment Management, Mr. Calhoun was a Director of Investments at Oppenheimer & Co. Mr. Calhoun holds the Series 63 (Uniform Securities Agent State Law) and 65 (Uniform Investment Advisor Law) securities licenses. He has previously taken and passed the Series 7 (General Securities Representative) and Series 9/10 (General Securities Sales Supervisor) securities exams.
Joe proudly served in the U.S. Navy’s nuclear submarine service for 8 years (1983-1990) and was awarded several commendations including the Navy Achievement Medal in 1987. He studied engineering at the University of South Carolina and is a graduate of the U.S. Navy’s Nuclear Propulsion School. He founded Alhambra Investment Management as a registered investment advisory to address the needs of the individual investor. His market commentaries are widely read and published at various online outlets. He has appeared on Larry Kudlow’s program on CNBC and various radio programs. He is also an editor of the website RealClearMarkets.com.
Bert Hochfeld is a convicted felon and former hedge fund manager. He was convicted of mis-appropriating funds from his hedge fund in 2012. .Bert started his business career at IBM working in the areas of product planning and pricing after completing military service Bert worked for IBM in the late 1960's and early 1970's before he took as a post as head of sales and marketing for Memorex Telex and worked there for most of the 1970's until he joined Raytheon Data Systems in a similar capacity in the 1980's. Bert briefly became a real estate developer in the Boston area before joining BMC Software as a product planning director in the late 1980's and early 1990's. Subsequent to that he entered the brokerage business where he became an enterprise software analyst, first at Louis Nicoud and then at Josephthal.&; Co. After Josephthal closed Bert started his own independent research consultancy specializing in enterprise software, storage and IT outsourcing. Bert also ran a small hedge fund. After his arrest and conviction, Bert closed both of those ventures and have been on a sabbatical the past few years. Bert currently manage his own money and those of a few close friends. All of these investments are in tech and we also take positions in small start-up ventures. ..
Harvard College, BA, Economics; Stanford Graduate School of Business, MBA
Managing Director, Boslego Risk Services
I founded Boslego Risk Services and became a recognized expert in the area of energy price risk management (hedging), providing oil and natural gas hedging strategies to major oil companies such as Exxon, Shell, Mobil, Chevron, Texaco and Phillips; to the national oil companies of Norway, Venezuela, Mexico, Canada, France and Italy; to major users of energy products, such as Delta Airlines, United Airlines, Burlington-Northern Railroad, and Canadian Pacific Railway; to major trading firms, such as Enron, Phibro, Sempra and Vitol; and to large hedge funds (confidential).
As the recognized expert in energy hedging, I was selected by the former president, John Treat, of the New York Mercantile Exchange (NYMEX) to write the chapter on hedging in his book, Energy Futures.
I expanded my risk analysis and hedging services beyond the energy markets to financial markets. Given the failure of traditional portfolio diversification to limit losses to levels tolerable to most investors in 2008/09, I created investment strategies utilizing risk management techniques for hedge funds and financial firms.
On October 31st, 2014, I retired. Turned in the keys to the company car, gave them my computer and my account lists and joined the ranks of those who "slipped off into the sunset." I never thought in retirement that I would be this busy. It's fun. Time with the grandkids, time to perfect my cooking skills, and time to travel and check off the things on my bucket list. I should have done this a long time ago.
A lifelong student of the markets, speculator, and investor, decades of experience have forged Adam into a hardcore contrarian. He believes in buying low when others are afraid, then later selling high when others are brave. He founded the financial-market research company Zeal LLC, and continues to write acclaimed weekly and monthly subscription newsletters.
Brian is the founder of Investor in the Family and Online Investor Conference.
At Investor in the Family (http://investorinthefamily.com/), Brian's goal is to help protect investors from making big mistakes that jeopardize their portfolios and financial futures.
The Online Investing Conference (http://onlineinvestingconference.com/) was created to help link self-directed investors with carefully filtered and proven investing professionals to help save investors both time and money while building a portfolio that outperforms.
If you'd like to connect or learn more, please feel free to send a private message via Seeking Alpha platform.
I'm a trader who trades both short-term and long-term. I started my career as a day-trader for a trading firm, but then turned to longer time frames and went on my own to manage my portfolio.
I use technical analysis as well as fundamental analysis in my research.
Allan Harris is an outspoken advocate for technical analysis via pattern recognition as the only effective methodology for making money trading the stock market. Allan has been involved in the markets for 40 years, starting as an options trader while attending law school in the late 1970's and ultimately becoming a professional trader after retiring from the practice of law in 1994. A prolific contributor to various stock market forums, including the Gilder Technology Forum in the 1990's, he started his own free stock market blog in 2004 that later evolved into AllanTrends.com, a subscription based trading service based upon a proprietary trend identification algorithm. Using a novel staggered profit taking strategy his service trades intermediate and short term trends in a basket of stocks and ETF's with outstanding trending characteristics.
Brandon is a senior in the Gabelli School of Business at Fordham University. He actively invests on his own personal time, utilizing contrarian strategies. He is an incoming S&T analyst at a BB next summer.
Brandon is originally from Los Angeles, California where he studied at Loyola High School.
If you need to get in contact with him, feel free to e-mail him at email@example.com - Thank you for your time.
The SA Marketplace is Seeking Alpha's platform for exclusive premium services from some of our top authors. Authors provide specialized, focused services that as a whole cover a wide variety of investment styles, giving readers a chance to get more insight on their preferred approach.
Check out all our authors here. This account will be used to highlight these authors and offer insights into investing from the authors to any interested users. Follow this account if you'd like to hear what's going on with the SA marketplace!
For any questions about SA's Marketplace, contact subscriptions at seekingalpha.com. We'd be happy to hear from you.
Alberta Contributor is a mechanical engineering diploma holder with over 15 years experience in engineering, management, and investment. AC is an author of HOW NOT TO LOSE MONEY IN THE STOCK MARKET: http://seekingalpha.com/article/4022446-lose-money-stock-market
Scouting for fundamentally-strong companies that are capable of doing well in any market. My approach will involve scanning financials, studying the industry, and link the two to provide investment advice.
My extensive experience working overseas has provided a solid foundation for my investment philosophy.
I have found that travel is a far better teacher than a conventional education. The experiences and knowledge one gains on the ground around the world cannot be taught in any classroom.
Ian’s Insider Corner research focuses primarily on long-term dividend-paying companies with stable and reliable growth, stocks suitable for individual retirement accounts. Ian also looks for “niche” shorter-term trading opportunities, and coverage. During the 3-years Ian worked at Kerrisdale Capital, the New York-based activist hedge fund had great success exposing fraudulent companies. Kerrisdale Capital returned almost 200% in 2011, and more than 300% in total. Ian Bezek offers in-depth coverage of all the stocks in his “IMF” portfolio.